by Jon Fleetwood,Jon Fleetwood:
Follows major German court rulings forcing disclosure of internal COVID vaccine safety and manufacturing records.
BioNTech has announced that it plans to shut down major portions of its COVID-19 vaccine manufacturing network, close multiple facilities, eliminate approximately 1,860 jobs, and consolidate operations as revenues from its COVID-19 vaccine business continue to decline.
The move comes after major German court rulings forced BioNTech tohand overinternal COVID-19 vaccine safety, toxicity, manufacturing, biodistribution, residual DNA, and spike protein data in vaccine injury litigation, while a higher appellate courtoverturneda lower ruling favoring the company and ordered a full re-examination of evidence tied to alleged life-altering post-vaccination injuries.
TRUTH LIVES on athttps://sgtreport.tv/
According to BioNTech’s official first quarter 2026 financial resultspress releaseposted on Tuesday:
“BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts.”
“BioNTech plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac’s sites, affecting up to approximately 1,860 positions in total. The exit from the sites in Idar-Oberstein, Marburg, and Tübingen is planned by the end of 2027, while operations in Singapore are expected to conclude in Q1 2027.”
BioNTech also disclosed that it is exploring the sale of the affected facilities:
“For each of these manufacturing sites, BioNTech is exploring divestment options, including a partial or total sale.”
Source: SGT Report
